Life Science REIT plc announced that Richard Howell, currently a non-executive Director of the Company, will take on the role of Senior Independent Director. The Company also confirms his appointment, further to the announcement on 3 May 2022, as Chair of the Audit and Risk Committee. Both appointments are with effect from June 24, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.6 GBX | +0.30% | +0.90% | -46.84% |
03-27 | Jefferies Downgrades Life Science REIT to Hold from Buy, Cuts PT | MT |
03-27 | Sorted renews M&S deal; Tribe completes drill build | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-46.84% | 149M | |
+10.51% | 29.38B | |
+13.37% | 26.28B | |
+5.22% | 21.98B | |
+9.78% | 17.48B | |
+6.06% | 16.66B | |
-9.96% | 15B | |
+3.34% | 13.61B | |
+7.47% | 13.55B | |
-7.67% | 12.15B |
- Stock Market
- Equities
- LABS Stock
- News Life Science REIT plc
- Life Science Reit plc Announces Change of Role of Richard Howell from Non-Executive Director to Senior Independent Director and Appointment as Chair of the Audit and Risk Committee